ClinicalTrials.gg
CompletedNCT00171340Updated Apr 16, 2012Results posted

Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

A Phase 3 interventional study of Zoledronic acid and Letrozole in Bone Loss and Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 106 sites in 28 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2012-04-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,065
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing Zoledronic Acid in Bone Diseases, Metabolic — 1 open to participants now, 1 under way, none of them phase 3. Zoledronic Acid · Bone Diseases, Metabolic.

Enrollment
2nd of 25
1,065 · median 135
Started
2003
with 4 others
Phase 3
9 of 25
none open now
Registered
11th of 25
by date
Lead sponsor
8 of 25
Novartis Pharmaceuticals

Among the 25 studies testing Zoledronic Acid in Bone Diseases, Metabolic, this one is the 2nd largest by enrollment, is one of 5 that started in 2003, is one of 9 in phase 3, and was the 11th registered.

Bone Diseases, Metabolic

662 studies on the registry are indexed under Bone Diseases, Metabolic; 94 are open to participants now.

Browse Bone Diseases, Metabolic studies →

Open to participants now

1 of the 25 studies testing Zoledronic Acid in Bone Diseases, Metabolic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Zoledronic Acid

Zoledronic Acid: first FDA approval 2001 (ZOMETA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Zoledronic Acid in Bone Diseases, Metabolic, or all of them as a file.
02

Study summary

Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every 6 months or delayed start zoledronic acid 4 mg IV 15-minute infusion every 6 months. Delayed start zoledronic acid will be initiated when either the Bone Mineral Density T-score is below -2 Standard Deviations at either the lumbar spine or hip or any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the month 36 scheduled visit. Letrozole 2.5 mg will be given daily for 5 years.

03

Conditions studied

  • Bone Loss
  • Breast Cancer

Keywords

  • Bone Loss
  • Osteopenia
  • Breast cancer
  • letrozole
  • zoledronic acid
  • postmenopausal
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage I-IIIa breast cancer
  • or recently postmenopausal
  • Recent surgery for breast cancer
  • Estrogen Receptor positive and/or progesterone receptor positive hormone receptor status
  • No prior treatment with letrozole

Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • disease
  • Invasive bilateral disease
  • Clinical or radiological evidence of existing fracture in spine or hip
  • Prior treatment with IV bisphosphonates in the past 12 months
  • Current treatment with oral bisphosphonates ( must be discontinued within 3 weeks of baseline evaluation)
  • Use of Tibolone within 6 months
  • Prior use of parathyroid hormone for more than 1 week
  • Previous or concomitant
  • Abnormal renal function
  • History of disease effecting bone metabolism

Other protocol-defined exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,065 participants (actual)

Study arms

  • Experimental
    Upfront Zoledronic Acid

    Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.

    Drug: Zoledronic acid · Drug: Letrozole

  • Experimental
    Delayed Zoledronic Acid

    Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score \<= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.

    Drug: Zoledronic acid · Drug: Letrozole

Interventions

  • Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.

    Also known as: ZOL446, Zometa®

  • Letrozole tablets 2.5 mg/day taken orally for 5 years.

    Also known as: Femara®

06

What researchers measure

Primary outcomes

  1. Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.

    Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA).

    Time frame: Baseline, 12 months

Secondary outcomes

  1. Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 2, 3, 4 and 5 Years of Therapy.

    Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)

    Time frame: Baseline, 2 years. Baseline, 3 years. Baseline, 4 years. Baseline, 5 years.

  2. Percentage Change in Bone Mineral Density (BMD)of the Lumbar Spine (L1-L4) Over 5 Years of Therapy.

    Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L1-L4)as measured by dual energy x-ray absorptiometry (DXA)

    Time frame: Baseline, 5 years.

  3. Percentage Change in Bone Mineral Density (BMD) of the Total Hip at 12 Months, 2 Years, 3 Years, 4 Years and 5 Years After Therapy.

    Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)

    Time frame: Baseline, 12 months. Baseline, 2 years. Baseline, 3 years. Baseline, 4 years. Baseline, 5 years.

  4. Percentage of Participants With Clinical Fractures at 3 Years of Therapy Which Were Not Present at Baseline

    At 3 years of therapy the percentage of participants with fractures as detected by X-ray and/ or bone scan.

    Time frame: Baseline,3 years

07

Results

Posted May 26, 2011

Participant flow

Participant flow — Overall Study
MilestoneZoledronic Acid 4 mg UpfrontZoledronic Acid 4 mg Delayed
Started532533
Completed408398
Not completed124135
Withdrew: Adverse event4642
Withdrew: Lack of efficacy2941
Withdrew: Protocol violation78
Withdrew: Withdrawal by subject2219
Withdrew: Lost to follow-up05
Withdrew: Abnormal laboratory results20
Withdrew: Abnormal test procedure results611
Withdrew: No longer required study drug11
Withdrew: Administrative problems52
Withdrew: Death66

Outcome measures

PrimaryPercentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.

Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA).

Time frame:
Baseline, 12 months
Reported as:
Mean · Percentage change in BMD
Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.
Percentage change in BMDZoledronic Acid 4 mg UpfrontZoledronic Acid 4 mg Delayed
Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.2.208 ± 3.4194-3.617 ± 4.2151
SecondaryPercentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 2, 3, 4 and 5 Years of Therapy.

Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)

Time frame:
Baseline, 2 years. Baseline, 3 years. Baseline, 4 years. Baseline, 5 years.
Reported as:
Mean · Percentage change in BMD
Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 2, 3, 4 and 5 Years of Therapy.
Percentage change in BMDZolendronic Acid 4 mg UpfrontZolendronic Acid 4 mg Delayed
At 2 years (n=339,343)3.463 ± 4.2691-4.601 ± 5.5273
At 3 years (n=313,311)3.730 ± 4.884-4.871 ± 6.271
At 4 years (n=290,294)3.782 ± 5.7300-5.154 ± 7.1079
At 5 years (n=264,264)4.308 ± 6.0242-5.414 ± 7.6185
SecondaryPercentage Change in Bone Mineral Density (BMD)of the Lumbar Spine (L1-L4) Over 5 Years of Therapy.

Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L1-L4)as measured by dual energy x-ray absorptiometry (DXA)

Time frame:
Baseline, 5 years.
Reported as:
Mean · Percentage change in BMD
Percentage Change in Bone Mineral Density (BMD)of the Lumbar Spine (L1-L4) Over 5 Years of Therapy.
Percentage change in BMDZolendronic Acid 4 mg UpfrontZolendronic Acid 4 mg Delayed
At 12 months (n=360,369)2.128 ± 3.2106-3603 ± 4.1808
At 2 years (n=339,343)3.300 ± 4.0700-4.521 ± 5.2624
At 3 years (n=313,311)3.521 ± 4.5936-4.869 ± 6.0310
At 4 years (n=290,294)3.529 ± 5.5410-5.148 ± 6.8803
At 5 years (n=264,264)3.898 ± 5.7995-5.427 ± 7.4818
SecondaryPercentage Change in Bone Mineral Density (BMD) of the Total Hip at 12 Months, 2 Years, 3 Years, 4 Years and 5 Years After Therapy.

Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)

Time frame:
Baseline, 12 months. Baseline, 2 years. Baseline, 3 years. Baseline, 4 years. Baseline, 5 years.
Reported as:
Mean · Percentage change in BMD
Percentage Change in Bone Mineral Density (BMD) of the Total Hip at 12 Months, 2 Years, 3 Years, 4 Years and 5 Years After Therapy.
Percentage change in BMDZolendronic Acid 4 mg UpfrontZolendronic Acid 4 mg Delayed
At 12 months (n=419,434)1.222 ± 2.3257-2.239 ± 3.3614
At 2 years (n=394,393)1.649 ± 2.7333-2.990 ± 4.4318
At 3 years (n=376,365)1.754 ± 3.1375-3.302 ± 4.8942
At 4 years (n=336,349)1.716 ± 3.5228-3.922 ± 5.6505
At 5 years (n=306,314)1.615 ± 3.7490-4.162 ± 6.0270
SecondaryPercentage of Participants With Clinical Fractures at 3 Years of Therapy Which Were Not Present at Baseline

At 3 years of therapy the percentage of participants with fractures as detected by X-ray and/ or bone scan.

Time frame:
Baseline,3 years
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinical Fractures at 3 Years of Therapy Which Were Not Present at Baseline
Percentage of ParticipantsZoledronic Acid 4 mg UpfrontZoledronic Acid 4 mg Delayed
Percentage of Participants With Clinical Fractures at 3 Years of Therapy Which Were Not Present at Baseline0.61.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zoledronic Acid 4mg Upfront—133/525 (25.3%)477/525 (90.9%)
Zolendronic Acid 4mg Delayed—124/535 (23.2%)486/535 (90.8%)
Most frequent serious events
Showing 10 of 273
Most frequent serious events
EventZoledronic Acid 4mg UpfrontZolendronic Acid 4mg Delayed
CholelithiasisHepatobiliary disorders4/52510/535
FallInjury, poisoning and procedural complications7/5257/535
OsteoarthritisMusculoskeletal and connective tissue disorders5/5257/535
PyrexiaGeneral disorders5/5253/535
Urinary tract infectionInfections and infestations4/5251/535
OsteonecrosisMusculoskeletal and connective tissue disorders4/5251/535
Atrial fibrillationCardiac disorders1/5254/535
Chest painGeneral disorders2/5254/535
PneumoniaInfections and infestations0/5254/535
Angina pectorisCardiac disorders3/5252/535
Most frequent other events
Showing 10 of 31
Most frequent other events
EventZoledronic Acid 4mg UpfrontZolendronic Acid 4mg Delayed
ArthralgiaMusculoskeletal and connective tissue disorders256/525251/535
Hot flushVascular disorders152/525163/535
Bone painMusculoskeletal and connective tissue disorders97/52564/535
FatigueGeneral disorders93/52595/535
Pain in extremityMusculoskeletal and connective tissue disorders69/52580/535
Back painMusculoskeletal and connective tissue disorders78/52578/535
PyrexiaGeneral disorders76/52517/535
HeadacheNervous system disorders75/52563/535
MyalgiaMusculoskeletal and connective tissue disorders68/52571/535
HypercholesterolaemiaMetabolism and nutrition disorders58/52560/535

Baseline characteristics

Age Continuous
Age Continuous(Years)Zoledronic Acid 4 mg UpfrontZoledronic Acid 4 mg DelayedTotal
Median57 ± (36-87)58 ± (37-81)57 (36 to 87)
Sex: Female, Male
Sex: Female, Male(Participants)Zoledronic Acid 4 mg UpfrontZoledronic Acid 4 mg DelayedTotal
Female5325331065
Male000
08

Study locations

106 sites
  • Novartis Investigative Site
    Buenos Aires, Argentina
  • Novartis Investigative Site
    Rosario Santa Fe, Argentina
  • Novartis Investigative Site
    New South Wales, Australia
  • Novartis Investigative Site
    Perth, Australia
  • Novartis Investigative Site
    South Australia, Australia
  • Novartis Investigative Site
    Victoria, Australia
  • Novartis Investigative Site
    Bonheiden, Belgium
  • Novartis Investigative Site
    Brasschaat, Belgium
  • Novartis Investigative Site
    Brussels, Belgium
  • Novartis Investigative Site
    Leuven, Belgium
  • Novartis Investigative Site
    Wilrijk, Belgium
  • Novartis Investigative Site
    Porto Alegre, Brazil
  • Novartis Investigative Site
    Sao Paulo, Brazil
  • Novartis Investigative Site
    Santiago, Chile
  • Novartis Investigative Site
    Beijing, China
  • Novartis Investigative Site
    Shanghai, China
  • Novartis Investigative Site
    Medellin, Colombia
  • Novartis Investigative Site
    Nemocnice, Czech Republic
  • Novartis Investigative Site
    Cairo, Egypt
  • Novartis Investigative Site
    Pori, Finland
  • Novartis Investigative Site
    Turku, Finland
  • Novartis Investigative Site
    Bordeaux Cedex, France
  • Novartis Investigative Site
    Le Havre, France
  • Novartis Investigative Site
    Montpellier Cedex, France
  • Novartis Investigative Site
    Poitiers Cedex, France
  • Novartis Investigative Site
    St. Cloud, France
  • Novartis Investigative Site
    Augsberg, Germany
  • Novartis Investigative Site
    Berlin, Germany
  • Novartis Investigative Site
    Ebersberg, Germany
  • Novartis Investigative Site
    Frankfurt, Germany
  • Novartis Investigative Site
    Halberstadt, Germany
  • Novartis Investigative Site
    Hamburg, Germany
  • Novartis Investigative Site
    Hoyerswerda, Germany
  • Novartis Investigative Site
    Kassel, Germany
  • Novartis Investigative Site
    Kiel, Germany
  • Novartis Investigative Site
    Muenchen, Germany
  • Novartis Investigative Site
    Munich, Germany
  • Novartis Investigative Site
    Neunkirchen, Germany
  • Novartis Investigative Site
    Rostock, Germany
  • Novartis Investigative Site
    Stadthagen, Germany
  • Novartis Investigative Site
    Stendal, Germany
  • Novartis Investigative Site
    Trier, Germany
  • Novartis Investigative Site
    Tubingen, Germany
  • Novartis Investigative Site
    Wiesbaden, Germany
  • Novartis Investigative Site
    Guatemala City, Guatemala
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Ancona, Italy
  • Novartis Investigative Site
    Aviano, 33081, Italy
  • Novartis Investigative Site
    Bergamo, Italy
  • Novartis Investigative Site
    Catanzaro, 88100, Italy
  • Novartis Investigative Site
    Firenze, 50139, Italy
  • Novartis Investigative Site
    Genova, Italy
  • Novartis Investigative Site
    Meldola, Italy
  • Novartis Investigative Site
    Modena, Italy
  • Novartis Investigative Site
    Orbassano Torino, Italy
  • Novartis Investigative Site
    Perugia, Italy
  • Novartis Investigative Site
    Torino, Italy
  • Novartis Investigative Site
    Varese, Italy
  • Novartis Investigative Site
    Gyeonggi, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 110, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 137, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 138, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 139, Korea, Republic of
  • Novartis Investigative Site
    Distrito Federal, Mexico
  • Novartis Investigative Site
    Almere, Netherlands
  • Novartis Investigative Site
    Arnhem, Netherlands
  • Novartis Investigative Site
    Den Haag, Netherlands
  • Novartis Investigative Site
    Ede, Netherlands
  • Novartis Investigative Site
    Eindhoven, Netherlands
  • Novartis Investigative Site
    Hoogeveen, Netherlands
  • Novartis Investigative Site
    Leiden, Netherlands
  • Novartis Investigative Site
    Nijmegen, Netherlands
  • Novartis Investigative Site
    Utrecht, Netherlands
  • Novartis Investigative Site
    Hamilton, New Zealand
  • Novartis Investigative Site
    Wellington, New Zealand
  • Novartis Investigative Site
    Jesus Maria, Peru
  • Novartis Investigative Site
    La Victoria, Peru
  • Novartis Investigative Site
    Surquillo, Peru
  • Novartis Investigative Site
    Cebu City, Philippines
  • Novartis Investigative Site
    Quezon City, Philippines
  • Novartis Investigative Site
    Coimbra, Portugal
  • Novartis Investigative Site
    Barcelona, Spain
  • Novartis Investigative Site
    Cordoba, Spain
  • Novartis Investigative Site
    Gea, Spain
  • Novartis Investigative Site
    Ibanez, Spain
  • Novartis Investigative Site
    La Maso, Spain
  • Novartis Investigative Site
    Villaroel, Spain
  • Novartis Investigative Site
    Bern, Switzerland
  • Novartis Investigative Site
    Locarno, Switzerland
  • Novartis Investigative Site
    Lugano, Switzerland
  • Novartis Investigative Site
    Chang Hwa, 500, Taiwan
  • Novartis Investigative Site
    Taipei, 100, Taiwan
  • Novartis Investigative Site
    Taipei, 105, Taiwan
  • Novartis Investigative Site
    Taipei, 112, Taiwan
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Bangkok, Thailand
  • Ratchathew
    Khonkaen, 40002, Thailand
  • Novartis Investigative Site
    Birmingham, United Kingdom
  • Novartis Investigative Site
    Essex, United Kingdom
  • Novartis Investigative Site
    Manchester, United Kingdom

Showing the first 100 of 106 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013 Feb;24(2):398-405. doi: 10.1093/annonc/mds277. Epub 2012 Oct 9. PubMed 23047045 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 15, 2005
Start
May 2003
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Results first posted
May 26, 2011
Last update
Apr 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00171340
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
May 2003
Primary completion
Feb 2010
Completion
Feb 2010
Results posted
May 26, 2011
Last update
Apr 16, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zoledronic Acid · Letrozole

Start the discussion